Have a feature idea you'd love to see implemented?
Let us know!
MRUS Merus NV
Price (delayed)
$52.69
Market cap
$3.59B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.92
Enterprise value
$2.98B
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed
Highlights
Merus's equity has soared by 190% YoY and by 114% from the previous quarter
Merus's quick ratio has surged by 140% YoY and by 93% QoQ
The EPS has grown by 24% YoY but it has contracted by 5% from the previous quarter
Merus's net income has decreased by 12% from the previous quarter but it has increased by 6% YoY
Merus's gross profit has decreased by 15% YoY and by 8% QoQ
The revenue has declined by 15% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of MRUS
Market
Valuations
Earnings
Shares outstanding
68.21M
Market cap
$3.59B
Enterprise value
$2.98B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.14
Price to sales (P/S)
92.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
84.55
Revenue
$35.19M
EBIT
-$176.6M
EBITDA
-$174.08M
Free cash flow
-$104.19M
Per share
Balance sheet
Liquidity
EPS
-$2.92
Free cash flow per share
-$1.68
Book value per share
$12.72
Revenue per share
$0.57
TBVPS
$14.4
Total assets
$892.23M
Total liabilities
$145.46M
Debt
$11.02M
Equity
$746.77M
Working capital
$725.69M
Debt to equity
0.01
Current ratio
9.97
Quick ratio
9.76
Net debt/EBITDA
3.55
Margins
Efficiency
Dividend
EBITDA margin
-494.6%
Gross margin
100%
Net margin
-476.4%
Operating margin
-560%
Return on assets
-28.7%
Return on equity
-36.3%
Return on invested capital
-85%
Return on capital employed
-21.8%
Return on sales
-501.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRUS stock price
How has the Merus stock price performed over time
Intraday
2.11%
1 week
2.61%
1 month
6.08%
1 year
159.56%
YTD
91.6%
QTD
5.46%
Financial performance
How have Merus's revenue and profit performed over time
Revenue
$35.19M
Gross profit
$35.19M
Operating income
-$197.09M
Net income
-$167.66M
Gross margin
100%
Net margin
-476.4%
The operating margin has contracted by 34% YoY and by 29% from the previous quarter
MRUS's net margin is down by 22% since the previous quarter and by 10% year-on-year
MRUS's operating income is down by 18% QoQ and by 14% YoY
Merus's gross profit has decreased by 15% YoY and by 8% QoQ
Growth
What is Merus's growth rate over time
Valuation
What is Merus stock price valuation
P/E
N/A
P/B
4.14
P/S
92.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
84.55
The EPS has grown by 24% YoY but it has contracted by 5% from the previous quarter
Merus's equity has soared by 190% YoY and by 114% from the previous quarter
The P/B is 17% less than the last 4 quarters average of 4.9
The P/S is 56% higher than the last 4 quarters average of 58.1
The revenue has declined by 15% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Merus business performance
The ROE has grown by 48% YoY and by 18% from the previous quarter
The ROA is up by 40% year-on-year and by 13% since the previous quarter
The ROS has contracted by 21% from the previous quarter and by 15% YoY
The ROIC has grown by 16% YoY but it has contracted by 13% from the previous quarter
Dividends
What is MRUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRUS.
Financial health
How did Merus financials performed over time
Merus's total assets has soared by 145% YoY and by 79% from the previous quarter
Merus's quick ratio has surged by 140% YoY and by 93% QoQ
MRUS's debt is 99% smaller than its equity
Merus's equity has soared by 190% YoY and by 114% from the previous quarter
MRUS's debt to equity has dropped by 80% year-on-year and by 67% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.